Amgen Announced At ESMO Saturday, Phase 3 DeLLphi-305 Data Showing IMDELLTRA + IMFINZI Reduced Death Risk By 58% In First-Line ES-SCLC Maintenance, With Median Overall Survival Of 21.1 Vs. 12.7 Months; One-Year Survival Of Nearly 80% Vs. 53%
Amgen Announced At ESMO Saturday, Phase 3 DeLLphi-305 Data Showing IMDELLTRA + IMFINZI Reduced Death Risk By 58% In First-Line ES-SCLC Maintenance, With Median Overall Survival Of 21.1 Vs. 12.7 Months; One-Year Survival Of Nearly 80% Vs. 53%
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed